Mammalian disorder of sexual development (Homo sapiens)

From WikiPathways

Jump to: navigation, search
3Regression of Müllarian DuctsSertoli CellTestisGranulosa CellGenital RidgeOvaryBipotential ridgeMale Internal GenetaliaMale External GenetaliaRSPO1FGFR2RBFOX2NR5A1PBX1SOX8AMHR2TestosteroneDMRT1FGF9FSTEMX2SOX9PTGDSMAPK11SRD5A1NR5A1WT1GATA4PGD2DHHAMHFOXL2GATA4INSL3NR5A1WT1NR5A1DHTSRYCTNNB1WNT4WT1CBX2SOX91121, 211


Description

Multiple genes in the genital ridge are of importance for the formation of the bipotential ridge. Several of these genes are WT1, EMX2, PBX1, and CBX2. After 7 weeks there is a differentiation between XY and XX gonads.

In the XX gonad, the absence of the gene SRY will result in the under expression of the SOX9 gene. This will have as a consequence that the SOX9 gene will not reach its threshold. Along with the expression of RSPO1 and WNT4, β-catenin is signalled and will lead to further inhibition of SOX9 and stimulation of FST and FOXL2. Both RSPO1 and WNT, as well as the combination of FST and FOXL2 are stimulated by NR5A1. This process will lead to the formation of the ovary due to the suppression of the formation of the testis, by inhibition of the genes. Due to the absence of androgens the female reproductive system can develop.


In the XY gonad the gene SRY is expressed in the pre-Sertoli cells leading to an upregulation of the SOX9 gene. In this upregulation NR5A1 has a promoting function to increase the SOX9 levels until it reaches its threshold level. once this level is reached a regulatory loop of FGF9 and PGD2 is activated to keep constant levels of SOX9. Another promoting factor of SOX9 is PGDS, this factor also stimulates the expression of SOX9. After the threshold levels are reached AMH is stimulated by SOX9. This stimulation is being catalysed by NR5A1, GATA4, WT1 and SOX8. AMH can then further stimulate AMHR2 and promote the regression of the Müllerian Ducts. AMH is possibly also involved in the suppression of genes involved in the formation of female structures, such as FOXL2 by DMRT1. When the Sertoli Cell is fully formed, it can induce the development of foetal Leydig cells via the DHH-pathway which produced INSL3. INSL3 is promoted by testosterone. Testosterone in itself is stimulated by NR5A1 and also stimulates the formation of 5-dihydrotestosterone (DHT). The stimulation of DHT is catalysed by SRD5A1. These factors together induce the formation of internal and external male genitalia.

Quality Tags

Ontology Terms

 

Bibliography

  1. Ostrer H; ''Disorders of sex development (DSDs): an update.''; J Clin Endocrinol Metab, 2014 PubMed Europe PMC Scholia
  2. Bashamboo A, McElreavey K; ''Mechanism of Sex Determination in Humans: Insights from Disorders of Sex Development.''; Sex Dev, 2016 PubMed Europe PMC Scholia
  3. Kyriakou, A, Lucas-Herald, A, McGowan, R, Tobias, E, Ahmed, F; ''Disorders of sex development: advances in genetic diagnosis and challenges in management ''; Dovepress, 2015

History

View all...
CompareRevisionActionTimeUserComment
110324view14:12, 4 May 2020FehrhartModified description
110294view14:21, 2 May 2020EgonwReplaced a secondary ChEBI identifiers with a primary identifier.
110283view07:55, 2 May 2020EgonwNot a mim-conversion
110279view07:12, 2 May 2020EgonwNot a mim-conversion
110262view15:31, 30 April 2020EgonwNot a mim-conversion
110076view09:02, 16 April 2020FehrhartOntology Term : 'sex differentiation disease' added !
110075view09:02, 16 April 2020FehrhartOntology Term : 'signaling pathway' added !
110074view09:02, 16 April 2020FehrhartOntology Term : 'sexual dysfunction' added !
110073view09:01, 16 April 2020FehrhartOntology Term : 'ovarian dysfunction' added !
110072view08:56, 16 April 2020FehrhartModified description
110071view08:55, 16 April 2020FehrhartCorrected format of reference, detangled graphics
109504view12:32, 20 March 2020FehrhartModified title
109310view14:18, 10 March 2020WoltersAAT1804Modified description
109309view14:18, 10 March 2020WoltersAAT1804New pathway

External references

DataNodes

View all...
NameTypeDatabase referenceComment
AMHGeneProductENSG00000104899 (Ensembl)
AMHR2GeneProductENSG00000135409 (Ensembl)
CBX2GeneProductENSG00000173894 (Ensembl)
CTNNB1GeneProductENSG00000168036 (Ensembl)
DHHGeneProductENSG00000139549 (Ensembl)
DHTMetaboliteHMDB0006770 (HMDB)
DMRT1GeneProductENSG00000137090 (Ensembl)
EMX2GeneProductENSG00000170370 (Ensembl)
FGF9GeneProductENSG00000102678 (Ensembl)
FGFR2GeneProductENSG00000066468 (Ensembl)
FOXL2GeneProductENSG00000183770 (Ensembl)
FSTGeneProductFST (HGNC)
GATA4GeneProductENSG00000136574 (Ensembl)
INSL3GeneProductENSG00000248099 (Ensembl)
MAPK11GeneProductENSG00000185386 (Ensembl)
NR5A1GeneProductENSG00000136931 (Ensembl)
PBX1GeneProductENSG00000185630 (Ensembl)
PGD2MetaboliteCHEBI:15555 (ChEBI)
PTGDSGeneProductENSG00000107317 (Ensembl)
RBFOX2GeneProductENSG00000100320 (Ensembl)
RSPO1GeneProductENSG00000169218 (Ensembl)
SOX8GeneProductENSG00000005513 (Ensembl)
SOX9GeneProductENSG00000125398 (Ensembl)
SRD5A1GeneProductENSG00000145545 (Ensembl)
SRYGeneProductENSG00000184895 (Ensembl)
TestosteroneMetaboliteCHEBI:17347 (ChEBI)
WNT4GeneProductENSG00000162552 (Ensembl)
WT1GeneProductENSG00000184937 (Ensembl)

Annotated Interactions

No annotated interactions

Personal tools